ZyVersa Therapeutics, Inc. (ZVSA)
0.2652
+0.10
(+65.44%)
USD |
OTCM |
Jan 09, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.147M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -77.53% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL. |
| URL | http://www.zyversa.com |
| Investor Relations URL | https://investors.zyversa.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 19, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL. |
| URL | http://www.zyversa.com |
| Investor Relations URL | https://investors.zyversa.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 19, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |